Search Clinical Trials in the European Union

Duration
Visits
Safety phase (I)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
641-660 of 936 trials

Inflammatory Bowel Disease: Risankizumab-800CW Imaging Study

We are investigating the safety and effectiveness of a new imaging agent for patients with Inflammatory Bowel Disease. This study aims to improve how we visualize drug targeting and inflammation in the intestines.

Inflammatory Bowel Disease (IBD)1-2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementGastroenterologyInfectious Diseases

First-in-Human Trial of OX118

We are testing a new drug, OX118, in healthy volunteers to evaluate its safety and effects. This study aims to gather important information before it can be used in patients.

Immune System Diseases6-12 monthsSafety phase (I)Infectious DiseasesRheumatology

Advanced Solid Tumors: ALTA2618 Treatment

We are testing a new drug called ALTA2618 for patients with advanced solid tumors that have the AKT1 E17K mutation. The goal is to see how safe it is and how it affects tumor growth.

Advanced Solid Tumors with AKT1 E17K Mutation1-2 yearsSafety phase (I)Oncology

Heart Failure: Hyperpolarized MRI Study

We are investigating how the heart uses a substance called pyruvate in patients with heart failure. This study aims to see if a new imaging method can improve our understanding of heart metabolism.

Heart Failure>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementCardiologyInternal Medicine

BDT272: Safety and Dosing Study

We are testing a new drug called BDT272 in healthy volunteers to see how safe it is and how the body processes it. This study will help us understand its effects before further testing.

Moderate to Severe PainSafety phase (I)Neurology

Obesity: BI 456906 vs. Semaglutide

We are testing a new medication, BI 456906, in people with obesity to see how it affects liver function compared to semaglutide. This study aims to understand the potential benefits of different doses for managing obesity.

Obesity>2 yearsSafety phase (I)EndocrinologyInternal Medicine

Gestational Trophoblastic Neoplasias: Avelumab and Methotrexate Study

We are investigating a new treatment combining Avelumab and Methotrexate for individuals with low-risk gestational trophoblastic neoplasias. This study aims to see if this combination is a safe and effective first-line option.

Gestational Trophoblastic Tumor>2 yearsSafety phase (I)Efficacy phase (II)Gynecology and Obstetrics

CHF10073 Inhaled Drug Study

We are evaluating the safety and absorption of the inhaled drug CHF10073 in healthy adults, both alone and with itraconazole. This study aims to understand how the drug behaves in the body.

Idiopathic Pulmonary Fibrosis1-2 yearsSafety phase (I)Internal MedicinePulmonology

Ongoing Safety Study for Patients in Previous Trials

We are monitoring the safety of a treatment for patients who have participated in earlier studies. This study aims to ensure continued support and care for their health.

Chronic Lymphocytic Leukemia (CLL)B-cell Non-Hodgkin's Lymphoma (NHL)>2 yearsSafety phase (I)Post-Trial Drug AccessHematologyOncology

Advanced Solid Tumors: ALE.P02 Treatment Study

We are investigating a new antibody-drug conjugate, ALE.P02, for adults with certain advanced solid tumors. The study aims to evaluate its safety and how well it may work against these tumors.

Advanced or Metastatic Squamous Solid Tumors1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboCost ReimbursementOncology

Glioblastoma: 131I-TLX101 Treatment Study

We are testing a new treatment combined with standard care for patients newly diagnosed with glioblastoma. The goal is to find a safe dose and understand how well it works.

Glioblastoma Multiforme>2 yearsSafety phase (I)Oncology

Artificial Cornea for Severe Corneal Ulcers

We are studying a new human-made cornea for patients with advanced corneal ulcers that don't improve with standard treatments. The trial aims to assess its safety and effectiveness in these challenging cases.

Corneal Ulcer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOphthalmology

Hematologic Malignancies: Gene-Modified T Cell Therapy

We are exploring a new treatment using modified T cells for patients with certain blood cancers who have received a transplant from specific donors. The study aims to see if this approach is safe and effective.

Hematological Malignancies with Specific HLA-DPB1 MarkersSafety phase (I)Efficacy phase (II)HematologyInfectious Diseases

Advanced Solid Tumors: BMS986504 Study

We are investigating how the drug BMS986504 is processed in patients with advanced solid tumors that have a specific genetic deletion. This study may provide insights for future cancer treatments.

Malignant Solid Tumor1-2 yearsSafety phase (I)Oncology

HPV 16: FluBHPVE6E7 Vaccine Study

We are testing different doses of a new vaccine for women infected with HPV 16. The goal is to see if it helps improve their condition compared to a placebo.

Human Papilloma Virus Infection>2 yearsSafety phase (I)Gynecology and ObstetricsInfectious Diseases

Neuroblastoma: 177Lu-DOTATATE Therapy for Children

We are evaluating a new radioactive treatment for children with refractory or recurrent neuroblastoma. The study aims to find the safest dose and assess how well the treatment works.

Recurrent or Refractory Neuroblastoma≤3 monthsSafety phase (I)No PlaceboInvestigational MedicinesOncologyPediatrics

Multiple Sclerosis: Immune Cell Therapy

We are testing a new treatment using the patient's own immune cells for individuals with early signs of multiple sclerosis. The goal is to assess its safety and feasibility.

Multiple SclerosisSafety phase (I)Neurology

Metastatic Colorectal Cancer: FLIRT Treatment Study

We are testing a combination of chemotherapy and targeted therapy for patients with a specific type of metastatic colorectal cancer. This study aims to see if this new approach improves treatment outcomes.

Metastatic Colorectal Cancer>2 yearsSafety phase (I)Efficacy phase (II)GastroenterologyOncology

CAIX-Positive Cancer: 68Ga-OncoCAIX Imaging Agent

We are evaluating the safety of a new imaging agent for patients with CAIX-positive cancer. This study aims to ensure it is safe for use in future treatments.

Clear Cell Renal Cell CarcinomaSafety phase (I)Oncology

Chronic Lymphocytic Leukemia: APG-2575 Study

We are studying a new medication, APG-2575, for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. The trial will evaluate its safety and effectiveness alone and with other treatments.

Chronic Lymphocytic Leukemia (CLL)1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesHematologyOncology